Alendronate (Na)

Alendronate (Na) is aminobisphosphonate and inhibitor of osteoclast-mediated bone resorption. Chemically Alendronate (Na) is identified as (4-Amino-1-hydroxybutylidene)-bisphosphonic acid monosodium salt trihydtare. Alendronate (Na) is prepared by chemical synthesis. Alendronate (Na) is effective to treat osteoporosis (bone thinning) by increasing bone density in post menopausal women. At the cellular level, Alendronate (Na) shows preferential localization to sites of bone resorption, specifically under osteoclasts. The osteoclasts adhere normally to the bone surface but lack the ruffled border that is indicative of active resorption. Alendronate (Na) does not interfer with osteclast recruitment or attachment, but it does inhibit osteoclast activity. While incorporated in bone matrix, Alendronate (Na) is not pharmacologically active. Thus Alendronate (Na) must be continuously administered to suppress osteoclasts on newly formed resorption surface. Alendronate (Na) is administered orally.


Adult Dose
Dose: 10 mg
Single Dose: 10 (10)
Frequency: 24 hourly
Route: PO
Instructions: Must be taken atleast 1/2hr before the first food, beverage or medication of the day with plain water only. Patients should receive supplemental calcium and vitamin D, if dietary intake is inadequate.
Neonatal
Dose:
Single Dose:
Frequency:
Route:
Instructions: Not recommended in this age group
Paedriatic
Dose:
Single Dose:
Frequency:
Route:
Instructions: Not recommended in this age group
Characteristics
Alendronate is the derivative of Alendronate (Na). It is of Synthetic origin and belongs to Biphosphonate. It belongs to Biphosphonate Derivative pharmacological group.The Molecular Weight of Alendronate (Na) is 325.10.
Contraindications
Alendronate (Na) is contraindicated in conditions like Hypocalcaemia,Ulcers,Gastritis,Dysphagia,Vitamin D deficiency.
Effects
The severe or irreversible adverse effects of Alendronate (Na), which give rise to further complications include Peptic ulceration, Esophageal ulceration, Esophagus erosion.The symptomatic adverse reactions produced by Alendronate (Na) are more or less tolerable and if they become severe, they can be treated symptomatically, these include Headache, Nausea, Vomiting, Diarrhea, Constipation, Abdominal pain, Rashes, Gastritis, Heart burn, Dysphagia.
Indications
Alendronate (Na) is primarily indicated in conditions like Osteoporosis in men, Osteoporosis prophylaxis, Pagets disease, Prevention and treatment of corticosteroid-induced osteoporosis, Treatment of osteoporosis in post menopausal women, and can also be given in adjunctive therapy as an alternative drug of choice in Hypercalcaemia associated with malignancy, Non-tumour induced hypercalcemia, Osteolytic tumoral bone disease.
Interactions
Alendronate (Na) is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementAspirinCalciumCalcium salts reduce absorption of Bisphosphonates (e.g Alendronate). Since Alendronate may lower blood calcium level, so blood calcium level should be corrected prior to initiation of the thearpy. If taken at the same time it is likely that calcium suplements, antacids and other oral medication may interfere with the absorption of Alendronate (Na). Calcium-containing products should be taken at least 2 hours before or after alendronate.Multiple VitaminsConcurrent use may decrease the absorption of alendronate.Separate your doses of alendronate as far as possible from doses of multi vitamins.RanitidineIntravenous Radministration of Ranitidine was shown to double the bioavailablity of oral Alendronate (Na). These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.
Interfrence
Risks
Drug should not be given to Pregnant Mothers, and patients suffering from Kidney dysfunction.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.
Storage
Tab Store in a well closed container, Below 30°C. Protect from Sunlight and Moisture.
Warnings
Alendronate should be used with caution in patients with history of ulcers or any other gastrointestinal problems or difficulty in swallowing. Hypocalcemia must be corrected before initiating therapy with Alendorante, othere distrubances of mineral metabolism (such as vitamine D deficiency) should also be effectively treated. This medication should not be used by patients with more severe renal indufficiency with a creatinine clearance
Back to List

Any information that appears on this website page is provided for the purpose of general information. This website has been compiled in good faith by HMIS.Online. However, no guarantee is made as to the completeness, validity or accuracy of the information it contains.